News & Analysis on Clinical Trial Services & Contract Research And Development
According to the international medical humanitarian organisation Médecins Sans Frontières (MSF), the World Health Organisation (WHO) has failed to address the emergence of extensively drug-resistant (XDR) tuberculosis.
Sigma-Aldrich launches the first commercially available proteomics standard in which allows researchers to better assess proteomics strategies, troubleshoot protocols and normalise results from day to day and lab to lab.
Roche took the opportunity at the American Association for the Study of Liver Diseases (AASLD) meeting to disclose the results of its hepatitis C polymerase inhibitor, which exhibited viral reductions greater than current polymerase inhibitors.
Solvay Pharmaceuticals said it has decided to renew its clinical development contract with Quintiles for further five years.
The contract sales and marketing business will reach $5.2bn (€4bn) by 2011, as it represents an ideal outsourcing opportunity for pharma companies competing in this fast growing sector, according to new market research.
Italian pharmaceutical company Recordati has reported a net profit growth of 6.5 per cent to €18.5m in its third quarter results, as a slump in sales was offset by lower costs.
Scientists are looking into the possibility of using bacteria to make a new library of anti-cancer compounds that are usually too difficult to create synthetically. The discovery could provide the basis for developing useful new anti-cancer drugs.
French pharma company Servier has announced the launch of a new manufacturing facility and also the expansion of its existing operation in Ireland, an investment totalling €184m.
Canadian drug maker LAB International has announced its plan to acquire Texan PharmaForm in order to speed up the manufacture of its inhalable anti-pain drug, which will reach late stage clinical trials next year.